|
Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology |
Oct 2024 |
Histopathology |
Myelodysplastic Syndromes (MDS) |
|
Drug development in higher-risk myelodysplastic syndromes |
Oct 2024 |
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Treatment of lower-risk myelodysplastic syndromes |
Oct 2024 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature |
Oct 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Diagnosis of myelodysplastic syndromes: the classic and the novel |
Oct 2024 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes |
Oct 2024 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials |
Oct 2024 |
American Journal of Therapeutics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Oct 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
